Listing of Claims:

1-5. (Cancelled)

6. (Currently Amended) A pharmaceutical composition consisting essentially of ~~comprising~~ 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients ~~with a water content below about 1% water~~, said excipients consisting essentially of ~~comprising~~ anhydrous lactose, microcrystalline cellulose, magnesium stearate, and talc.

7. (Original) The pharmaceutical composition according to claim 6 in the form of a tablet, a power or a capsule.

8-12. (Cancelled)

13. (Currently Amended) The pharmaceutical composition according to claim 6 wherein the anhydrous lactose, microcrystalline cellulose, magnesium stearate, and talc ~~pharmaceutically acceptable excipients~~ are in a dry form.

14-15. (Cancelled)

16. (Previously Presented) The pharmaceutical composition according to claim 6, further comprising at least one sweetener, flavouring agent, colour or lubricant.

17-27. (Cancelled)

28. (Previously Presented) The pharmaceutical composition according to claim 6 in tablet form, wherein the tablet is formed by direct compression.

29. (Previously Presented) The pharmaceutical composition according to claim 6 consisting of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl] thiazolidine-2,4-dione or a pharmaceutically acceptable

salt thereof	9%
Microcrystalline cellulose	20%
Anhydrous lactose	66%
Magnesium Stearate	0.5%
Talc	4.5%.

30. (Previously Presented) The pharmaceutical composition according to claim 29 in the form of a tablet, a powder or a capsule.

31. (Previously Presented) The pharmaceutical composition according to claim 30 in tablet form, wherein the tablet is formed by direct compression.

32. (New) The pharmaceutical composition according to claim 6, wherein the excipients have a water content below about 1%.

33. (New) A tablet formed by direct compression of a composition that consists essentially of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients, said excipients consisting essentially of between 100 and 400,000 parts by weight of anhydrous lactose and between 111 and 10,000 parts by weight of microcrystalline cellulose, expressed in parts by weight per 100 parts of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl] thiazolidine-2,4-dione or one of its pharmaceutically acceptable salts.

34. (New) The tablet according to claim 33, further comprising magnesium stearate and talc.

35. (New) The tablet according to claim 33, wherein magnesium stearate constitutes between 2.78 and 500 parts by weight of the tablet, expressed in parts by

weight per 100 parts of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl] thiazolidine-2,4-dione or one of its pharmaceutically acceptable salts.

36. (New) The tablet according to claim 33, wherein the excipients are in a dry form.

37. (New) The tablet according to claim 33, further comprising a sweetener, flavouring agent, color, lubricant, or a combination thereof.

38. (New) The tablet according to claim 33, wherein the excipients have a water content below about 1%.